Letter to the editor: risk comorbidities of COVID-19 in Parkinson's disease patients in Germany.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Prevalence and outcomes of Covid-19 in Parkinson's disease: Acute settings and hospital.International review of neurobiology · 2022
   Article
2. Multiple sclerosis is not associated with an increased risk for severe COVID-19: a nationwide retrospective cross-sectional study from Germany.Neurological research and practice · 2021
   Article
3. [Neurovascular manifestations of COVID‑19].Der Nervenarzt · 2021
   Review
4. Clinical Profiles and Mortality of COVID-19 Inpatients with Parkinson's Disease in Germany.Movement disorders : official journal of the Movement Disorder Society · 2021
   Article
5. Characteristics and outcomes of elderly patients with Parkinson's disease hospitalized due to COVID‑19‑associated pneumonia.Medicine international
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as